MS4A13 Inhibitors
MS4A13 Inhibitors are diverse in their mechanisms of action, targeting various signaling pathways and cellular processes to indirectly influence the functional activity of MS4A13. Kinase inhibitors like staurosporine and genistein target the phosphorylation events that are often essential for the activation or stabilization of MS4A13 on the cell membrane. By blocking these kinases, the phosphorylation and subsequent function of MS4A13 may be compromised, leading to a decrease in its activity. Similarly, agents that disrupt cellular trafficking and protein transport, such as brefeldin A and monensin, could prevent the correct localization of MS4A13 to the cell membrane, a key determinant of its functional activity. Brefeldin A's inhibition of protein ADP-ribosylation factor and monensin's disruption of intracellular pH and sodium gradients can thereby indirectly lead to a reduction in MS4A13 activity.
Intracellular signaling cascades that affect the function of MS4A13 are also targets for inhibition. For instance, thapsigargin, by depleting intracellular Ca^2+ stores, can impact Ca^2+-dependent kinases that interact with MS4A13, while U0126 and PD168393 can influence the MAPK/ERK and EGFR pathways respectively, potentially reducing MS4A13 phosphorylation and function. LY294002 and wortmannin are PI3K inhibitors that can decrease AKT phosphorylation, which is crucial for various aspects of cellular function including those that may involve MS4A13, such as protein trafficking and signal transduction. Similarly, mTOR signaling is implicated in the regulation of protein synthesis and cell growth, and its inhibition by rapamycin could have downstream effects on the functional activity of MS4A13. SP600125 and SB203580, inhibitors of JNK and p38 MAPK, respectively, may affect transcription factors and stress response mechanisms that regulate the expression or activity of MS4A13.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor that can inhibit a wide range of protein kinases. It may indirectly inhibit MS4A13 activity by blocking kinases that phosphorylate MS4A13, which is essential for its activation or stabilization on the cell membrane. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor which can impede phosphorylation events necessary for the proper functioning of MS4A13. By hindering tyrosine kinases, genistein could reduce the phosphorylation of MS4A13, leading to its functional inhibition. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting the exchange of protein ADP-ribosylation factor, which could lead to a reduction in the translocation of MS4A13 to the cell membrane, therefore decreasing its functional activity. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts intracellular pH and sodium gradients. This disruption can affect the trafficking and localization of MS4A13, potentially leading to decreased functional activity due to mislocalization. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca^2+ ATPase (SERCA) which leads to the depletion of intracellular Ca^2+ stores. This can affect Ca^2+-dependent protein kinases that would normally interact with MS4A13, thereby inhibiting its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that can obstruct the MAPK/ERK pathway. By inhibiting MEK, U0126 may reduce the phosphorylation of MS4A13 by extracellular signal-regulated kinases, which are crucial for MS4A13 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can reduce AKT phosphorylation. This reduction can affect the cell survival and trafficking pathways that are important for MS4A13 function, leading to decreased activity. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
PD168393 is an irreversible EGFR inhibitor. By blocking EGFR tyrosine kinase activity, PD168393 could impair downstream signaling pathways that regulate the activity and localization of MS4A13. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. Inhibition of JNK can prevent the phosphorylation and subsequent activation of transcription factors that may regulate MS4A13 expression or function, resulting in decreased activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that blocks p38 MAPK activity. Inhibition of p38 MAPK might affect the cellular stress response mechanisms that can modulate the function or expression of MS4A13. | ||||||